PL4284356T3 - Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi - Google Patents

Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi

Info

Publication number
PL4284356T3
PL4284356T3 PL22708379.7T PL22708379T PL4284356T3 PL 4284356 T3 PL4284356 T3 PL 4284356T3 PL 22708379 T PL22708379 T PL 22708379T PL 4284356 T3 PL4284356 T3 PL 4284356T3
Authority
PL
Poland
Prior art keywords
compounds
treatment
attention deficit
hyperactivity disorder
deficit hyperactivity
Prior art date
Application number
PL22708379.7T
Other languages
English (en)
Inventor
Karl Ægir KARLSSON
Haraldur ÞORSTEINSSON
Original Assignee
3Z Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Application filed by 3Z Ehf filed Critical 3Z Ehf
Publication of PL4284356T3 publication Critical patent/PL4284356T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL22708379.7T 2021-01-29 2022-01-28 Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi PL4284356T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (1)

Publication Number Publication Date
PL4284356T3 true PL4284356T3 (pl) 2025-07-28

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22708379.7T PL4284356T3 (pl) 2021-01-29 2022-01-28 Związki do zastosowania w leczeniu zespołu nadpobudliwości psychoruchowej z deficytem uwagi

Country Status (12)

Country Link
US (2) US20240130995A1 (pl)
EP (1) EP4284356B1 (pl)
JP (1) JP7891230B2 (pl)
AU (1) AU2022215118A1 (pl)
CA (1) CA3206935A1 (pl)
ES (1) ES3038949T3 (pl)
HR (1) HRP20250747T1 (pl)
HU (1) HUE071725T2 (pl)
PL (1) PL4284356T3 (pl)
RS (1) RS66934B1 (pl)
SM (1) SMT202500238T1 (pl)
WO (1) WO2022162199A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
AU2004292966A1 (en) 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
US9408837B2 (en) 2008-05-28 2016-08-09 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
WO2014041035A1 (en) 2012-09-11 2014-03-20 Institució Catalana De Recerca I Estudis Avançats Diagnostic method for detecting an autoimmune disease and related subject-matter
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 t―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
BR112020008371A2 (pt) * 2017-10-27 2020-11-03 Esteve Pharmaceuticals, S.A. novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Also Published As

Publication number Publication date
EP4284356B1 (en) 2025-04-02
JP7891230B2 (ja) 2026-07-16
WO2022162199A2 (en) 2022-08-04
JP2024508372A (ja) 2024-02-27
US20240130995A1 (en) 2024-04-25
CA3206935A1 (en) 2022-08-04
EP4284356A2 (en) 2023-12-06
HRP20250747T1 (hr) 2025-08-15
WO2022162199A3 (en) 2022-09-15
HUE071725T2 (hu) 2025-09-28
RS66934B1 (sr) 2025-07-31
EP4284356C0 (en) 2025-04-02
AU2022215118A1 (en) 2023-08-17
AU2022215118A9 (en) 2024-05-16
SMT202500238T1 (it) 2025-07-22
ES3038949T3 (en) 2025-10-16
US20260199279A1 (en) 2026-07-16

Similar Documents

Publication Publication Date Title
IL290415A (en) Compounds with deuterium for use in cancer treatment
PT3668513T (pt) Ativadores da piruvato quinase para uso no tratamento de distúrbios do sangue
SMT202500241T1 (it) Elafibranor per uso nel trattamento di colangite biliare primitiva
EP3054935A4 (en) Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
IL266764A (en) Gaboxadol for use in methods of treating attention deficit/hyperactivity disorder
IL311136A (en) Anti-CD3 antibody for use in the treatment or prevention of cancer and molecules containing the antibody
PL4340842T3 (pl) Sotorasib do zastosowania w leczeniu nowotworów
IL261418A (en) Mazindol immediate-release/delayed-release multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder
PL4419526T3 (pl) Związki heterocykliczne do stosowania w leczeniu nowotworu
HUE071725T2 (hu) Vegyületek figyelemhiányos hiperaktivitási zavar kezelésében való alkalmazásra
PL2844277T3 (pl) Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD)
EP2806736A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT
PL3941465T3 (pl) Sposoby leczenia zespołu nadpobudliwości psychoruchowej z deficytem uwagi z zastosowaniem inhibitorów kdm1a, takich jak związek wafidemstat
IL278763A (en) Methods for treating attention deficit hyperactivity disorder
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii
MX2016014780A (es) Metodos y composiciones de dasotralina para el tratamiento del adhd.
HUE066554T2 (hu) Keverõ egység szennyvízkezelõ berendezésekben kezelt folyadékok keveréséhez
IL284953A (en) Methylphenidate compositions for treatment of attention deficit hyperactivity disorder
MX2016014768A (es) Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd.
IL232897B (en) Pacetopran for the treatment of attention, concentration and hyperactivity disorder
BRPI1014545A2 (pt) composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade
HK40065152A (en) Methylphenidate compositions for treatment of attention deficit hyperactivity disorder
PT3082798T (pt) Derivados de benzodioxol para uso no tratamento do défice de atenção e/ou hiperatividade
GB201415260D0 (en) Aerator For Use in sewage treatment
GB201415259D0 (en) Aerator for use in sewage treatment